Original Article
Ambulante Therapie von Aspergillosen bei hämatologischen und onkologischen Patienten
Gerlinde Egerer,
Gerlinde Egerer
Abteilung Ha¨matologie, Onkologie und Rheumatologie Medizinische Universita¨tsklinik Heidelberg, Heidelberg, Deutschland
Search for more papers by this authorGerlinde Egerer,
Gerlinde Egerer
Abteilung Ha¨matologie, Onkologie und Rheumatologie Medizinische Universita¨tsklinik Heidelberg, Heidelberg, Deutschland
Search for more papers by this authorFirst published: 23 April 2012
Korrespondenzadresse: PD Dr. med. Gerlinde Egerer, Abteilung Hämatologie, Onkologie und Rheumatologie, Medizinische Universitätsklinik Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Deutschland. Tel.: +49 6221 56-8002. Fax: +49 6221 56-6824. E-Mail: [email protected]
Interessenkonflikt: Die Autorin erklärt, dass sie Vortragshonorare von Pfizer und MSD erhält und Mitglied des nationalen Advisory Boards für Antimykotika von MSD ist.
Literatur
- 1 Pagano I, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies. The SEIFEM-2004 study. Haematologica 2006; 91: 1068–75.
- 2 Pagano I, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SIEFEM B-2004 study. Clin Infect Dis 2007; 45: 1161–70.
- 3 McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis 2001; 33: 641–7.
- 4 Walsh TJ, Anaissie EJ, Denning DW, et al. Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46(3): 327–60.
- 5 Di YM, Li CG, Xue CC, Zhou SF. Clinical drugs that interact with St. John’s wort and implication in drug development. Curr Pharm Des 2008; 14(17): 1723–42.
- 6 Herbrecht R, Denning DW, Patterson TF, et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347(6): 408–15.
- 7 Traunmüller F, Popovic M, Konz KH, Smolle-Jüttner FM, Joukhadar C. Efficacy and safety of current drug therapies for invasive aspergillosis. Pharmacology 2011; 88(3–4): 213–24.
- 8 Herbrecht R, Flückinger U, Gachot B, Ribaud P, Thiebaut A, Cordonnier C. Antifungal therapy in leukemia patients 2009 update of the ECIL 1 and ECIL 2 guidelines. http://www.ichs.org
- 9 Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Böhme A, Ruhnke M, Buchheidt D, et al. Treatment of invasive fungal infections in cancer patients – recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009; 88(2): 97–110.
- 10 Fachinformation Voriconazol (Vfend®), August 2011.
- 11 Nivoix Y, Levêque D, Herbrecht R, Koffel JC, Beretz L, Ubeaud-Sequier G. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008; 47(12): 779–92.
- 12 Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109(8): 1532–5.
- 13 Pappas PG, Kauffman CA, Andes D, et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48(5): 503–35.
- 14 Amigues I, Cohen N, Chung D, et al. Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010; 16(1): 46–52.
- 15 Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44(1): 2–12.
- 16 Raad II, Hanna HA, Boktour M, et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leucemia 2008; 22: 496–503.
- 17 Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004; 57(2): 218–22.
- 18 Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009; 53(3): 958–66.
- 19 Caillot D. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis. Acta Haematol 2003; 109(3): 111–8.
- 20 Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001; 33(8): e83–90.
- 21 Cornely OA, Maertens J, Bresnik M, et al., AmBiLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44(10): 1289–97.
- 22 Fachinformation Caspofungin (Cancidas®), September 2011.
- 23 van de Sande WW, Tavakol M, van Vianen W, Bakker-Woudenberg IA. The effects of antifungal agents to conidial and hyphal forms of Aspergillus fumigatus. Med Mycol 2010; 48(1): 48–55.
- 24 Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53(5): 337–49.
- 25 Kontoyiannis DP, Ratanatharathorn V, Young JA, et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 2009; 11(1): 89–93.
- 26 Fachinformation Micafungin (Mycamine®), August 2011.
- 27 http://www.clinicaltrials.gov identifier NCT00531479.
- 28 Maertens J, Glasmacher A, Herbrecht R, et al., Caspofungin Combination Therapy Study Group. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107(12): 2888–97.
- 29 Viscoli C, Herbrecht R, Akan H, et al.; Infectious Disease Group of the EORTC. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64(6): 1274–81.
